Kalman Somogyi

Kalman Somogyi

Auto-generated profile, based on publicly available information

Kalman Somogyi

Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Cancer Discovery
Verified
Journal Article
Closed access
ADAlberto Diaz-Jimenez
Alberto Diaz-Jimenez
ESEmily G. Shuldiner
Emily G. Shuldiner
KSKalman Somogyi
Kalman Somogyi
KSKaren Y. Shih
Karen Y. Shih
ÓGÓscar González-Velasco
Óscar González-Velasco
RDRocio DKFZ
Rocio DKFZ
Diverse fusions of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) are oncogenic drivers in lung adenocarcinoma. EML4–ALK variants have distinct breakpoints within EML4, but their functional differences remain poorly understood. In this study, we use somatic genome editing to generate autochthonous mouse models of EML4–ALK–driven lung tumors and show that variant 3 (V3) is more oncogenic than variant 1 (V1). By using multiplexed genome editing and quantifying the effects of 29 putative tumor-suppressor genes on V1- and V3-driven lung cancer growth, we show that many tumor-suppressor genes have variant-specific effects on tumorigenesis. Pharmacogenomic analyses further suggest that tumor genotype can influence therapeutic responses. Analysis of human EML4–ALK–positive lung cancers also identified variant-specific differences in their genomic landscapes. These findings suggest that EML4–ALK variants behave more like distinct oncogenes than a uniform entity and highlight the dramatic impact of oncogenic fusion partner proteins and coincident tumor-suppressor gene alterations on the biology of oncogenic fusion–driven cancers. Significance: EML4–ALK–driven lung cancer is treated as a uniform disease despite the presence of distinct fusion variants in patients. Our findings show that EML4–ALK variants are functionally distinct, which may have implications for the treatment of this cancer type and highlights the need to consider differences among variants of other oncogenic fusions.

12 January 2026
Verified
Other
Open access
PDF file
ADAlberto Diaz-Jimenez
Alberto Diaz-Jimenez
ESEmily G. Shuldiner
Emily G. Shuldiner
KSKalman Somogyi
Kalman Somogyi
KSKaren Y. Shih
Karen Y. Shih
ÓGÓscar González-Velasco
Óscar González-Velasco
RDRocio DKFZ
Rocio DKFZ
Supplementary Figure 2 show the increase tumorigenesis of V3 tumors in a different mouse model, the general cloning strategy to generate the triple sgRNA vectors, and the efficiency of GFP inactivation in EML4-Alk-driven autochthonous tumors.

12 January 2026
Verified
Other
Open access
PDF file
ADAlberto Diaz-Jimenez
Alberto Diaz-Jimenez
ESEmily G. Shuldiner
Emily G. Shuldiner
KSKalman Somogyi
Kalman Somogyi
KSKaren Y. Shih
Karen Y. Shih
ÓGÓscar González-Velasco
Óscar González-Velasco
RDRocio DKFZ
Rocio DKFZ
Supplementary Figure 8 shows histological analysis and quantification of cancer type marker gene expression and signaling protein phosphorylation in EML4-ALK V1 and V3 tumors of different tumor suppressor genotypes

12 January 2026
Verified
Other
Open access
PDF file
ADAlberto Diaz-Jimenez
Alberto Diaz-Jimenez
ESEmily G. Shuldiner
Emily G. Shuldiner
KSKalman Somogyi
Kalman Somogyi
KSKaren Y. Shih
Karen Y. Shih
ÓGÓscar González-Velasco
Óscar González-Velasco
RDRocio DKFZ
Rocio DKFZ
Supplementary Figure 15 shows additional data on the genomic landscape of human EML4-ALK-driven lung cancer, including breakpoints in EML4 and ALK for all samples in the EML4-ALK cohort, distribution of alteration counts for all genes queried in Foundation Medicine’s sequencing panel, genes with recurrent alterations that have not previously been shown to be altered in EML4-ALK-driven lung cancer, calculation of power to detect differences in mutation frequency between V1- and V3-driven tumors, and alteration counts for NOTCH genes and PTEN in samples with the indicated “long” and “short” EML4-ALK variants.

12 January 2026
Verified
Other
Open access
ADAlberto Diaz-Jimenez
Alberto Diaz-Jimenez
ESEmily G. Shuldiner
Emily G. Shuldiner
KSKalman Somogyi
Kalman Somogyi
KSKaren Y. Shih
Karen Y. Shih
ÓGÓscar González-Velasco
Óscar González-Velasco
RDRocio DKFZ
Rocio DKFZ
Supplementary Table 6 shows the prevalence of alterations in all genes assayed across the entire cohort of NSCLC samples with EML4-ALK fusions.

12 January 2026
Verified
Other
Open access
ADAlberto Diaz-Jimenez
Alberto Diaz-Jimenez
ESEmily G. Shuldiner
Emily G. Shuldiner
KSKalman Somogyi
Kalman Somogyi
KSKaren Y. Shih
Karen Y. Shih
ÓGÓscar González-Velasco
Óscar González-Velasco
RDRocio DKFZ
Rocio DKFZ
Supplementary Table 1 shows the frequency of mutations in the selected genes in EML4-ALK patients (from AACR Project GENIE) as well as inclusion criteria and major pathway or function